Go Pro
→ Labor Day Warning: The secret that called 1929 is flashing something new (From Weiss Ratings) (Ad)tc pixel Free VHI Stock Alerts

Vitalhub (VHI) Competitors

Vitalhub logo
C$8.04 -0.19 (-2.31%)
As of 04:00 PM Eastern
Compare

VHI vs. CARE, ADK, RHT, DOC, and ZMD

Should you buy Vitalhub stock or one of its competitors? Vitalhub's main competitors and comparable companies include Dialogue Health Technologies (CARE), DIAGNOS (ADK), Reliq Health Technologies (RHT), CloudMD Software & Services (DOC), and ZoomMed (ZMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Vitalhub compare to Dialogue Health Technologies?

Vitalhub (TSE:VHI) and Dialogue Health Technologies (TSE:CARE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Vitalhub currently has a consensus price target of C$13.00, indicating a potential upside of 61.69%. Given Vitalhub's stronger consensus rating and higher possible upside, research analysts clearly believe Vitalhub is more favorable than Dialogue Health Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Dialogue Health Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vitalhub has a beta of 1.136195, indicating that its share price is 14% more volatile than the broader market. Comparatively, Dialogue Health Technologies has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market.

25.6% of Vitalhub shares are owned by institutional investors. Comparatively, 47.0% of Dialogue Health Technologies shares are owned by institutional investors. 18.6% of Vitalhub shares are owned by company insiders. Comparatively, 11.7% of Dialogue Health Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vitalhub has higher revenue and earnings than Dialogue Health Technologies. Dialogue Health Technologies is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M4.01C$3.35MC$0.1267.00
Dialogue Health TechnologiesC$95.88M0.00-C$19.50M-C$0.30N/A

Vitalhub has a net margin of 5.89% compared to Dialogue Health Technologies' net margin of -19.73%. Vitalhub's return on equity of 2.79% beat Dialogue Health Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
Dialogue Health Technologies -19.73%-19.76%-10.01%

In the previous week, Vitalhub had 2 more articles in the media than Dialogue Health Technologies. MarketBeat recorded 2 mentions for Vitalhub and 0 mentions for Dialogue Health Technologies. Vitalhub's average media sentiment score of 0.47 beat Dialogue Health Technologies' score of 0.00 indicating that Vitalhub is being referred to more favorably in the media.

Company Overall Sentiment
Vitalhub Neutral
Dialogue Health Technologies Neutral

Summary

Vitalhub beats Dialogue Health Technologies on 14 of the 16 factors compared between the two stocks.

How does Vitalhub compare to DIAGNOS?

Vitalhub (TSE:VHI) and DIAGNOS (CVE:ADK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Vitalhub has higher revenue and earnings than DIAGNOS. DIAGNOS is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M4.01C$3.35MC$0.1267.00
DIAGNOSC$65.48K873.52-C$3.81M-C$0.04N/A

25.6% of Vitalhub shares are owned by institutional investors. Comparatively, 0.3% of DIAGNOS shares are owned by institutional investors. 18.6% of Vitalhub shares are owned by insiders. Comparatively, 16.8% of DIAGNOS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vitalhub has a net margin of 5.89% compared to DIAGNOS's net margin of -6,956.84%. DIAGNOS's return on equity of 11,659.44% beat Vitalhub's return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
DIAGNOS -6,956.84%11,659.44%-134.33%

Vitalhub has a beta of 1.136195, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, DIAGNOS has a beta of 0.500906, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, Vitalhub had 1 more articles in the media than DIAGNOS. MarketBeat recorded 2 mentions for Vitalhub and 1 mentions for DIAGNOS. DIAGNOS's average media sentiment score of 1.94 beat Vitalhub's score of 0.47 indicating that DIAGNOS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vitalhub
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
DIAGNOS
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Vitalhub currently has a consensus price target of C$13.00, indicating a potential upside of 61.69%. Given Vitalhub's stronger consensus rating and higher probable upside, equities analysts clearly believe Vitalhub is more favorable than DIAGNOS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
DIAGNOS
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Vitalhub beats DIAGNOS on 14 of the 17 factors compared between the two stocks.

How does Vitalhub compare to Reliq Health Technologies?

Vitalhub (TSE:VHI) and Reliq Health Technologies (CVE:RHT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Vitalhub has higher revenue and earnings than Reliq Health Technologies. Reliq Health Technologies is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M4.01C$3.35MC$0.1267.00
Reliq Health TechnologiesN/AN/AN/A-C$0.02N/A

25.6% of Vitalhub shares are owned by institutional investors. Comparatively, 2.8% of Reliq Health Technologies shares are owned by institutional investors. 18.6% of Vitalhub shares are owned by insiders. Comparatively, 1.8% of Reliq Health Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vitalhub has a beta of 1.136195, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Reliq Health Technologies has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

In the previous week, Vitalhub had 2 more articles in the media than Reliq Health Technologies. MarketBeat recorded 2 mentions for Vitalhub and 0 mentions for Reliq Health Technologies. Vitalhub's average media sentiment score of 0.47 beat Reliq Health Technologies' score of 0.00 indicating that Vitalhub is being referred to more favorably in the media.

Company Overall Sentiment
Vitalhub Neutral
Reliq Health Technologies Neutral

Vitalhub has a net margin of 5.89% compared to Reliq Health Technologies' net margin of -95.54%. Vitalhub's return on equity of 2.79% beat Reliq Health Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
Reliq Health Technologies -95.54%-221.64%-5.30%

Vitalhub presently has a consensus target price of C$13.00, indicating a potential upside of 61.69%. Given Vitalhub's stronger consensus rating and higher probable upside, analysts clearly believe Vitalhub is more favorable than Reliq Health Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Reliq Health Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Vitalhub beats Reliq Health Technologies on 14 of the 15 factors compared between the two stocks.

How does Vitalhub compare to CloudMD Software & Services?

Vitalhub (TSE:VHI) and CloudMD Software & Services (CVE:DOC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

25.6% of Vitalhub shares are held by institutional investors. Comparatively, 0.5% of CloudMD Software & Services shares are held by institutional investors. 18.6% of Vitalhub shares are held by company insiders. Comparatively, 0.1% of CloudMD Software & Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vitalhub has higher revenue and earnings than CloudMD Software & Services. CloudMD Software & Services is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VitalhubC$127.08M4.01C$3.35MC$0.1267.00
CloudMD Software & ServicesC$90.91M0.12-C$76.56M-C$0.23N/A

In the previous week, Vitalhub had 2 more articles in the media than CloudMD Software & Services. MarketBeat recorded 2 mentions for Vitalhub and 0 mentions for CloudMD Software & Services. Vitalhub's average media sentiment score of 0.47 beat CloudMD Software & Services' score of 0.00 indicating that Vitalhub is being referred to more favorably in the media.

Company Overall Sentiment
Vitalhub Neutral
CloudMD Software & Services Neutral

Vitalhub has a net margin of 5.89% compared to CloudMD Software & Services' net margin of -91.12%. Vitalhub's return on equity of 2.79% beat CloudMD Software & Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Vitalhub5.89% 2.79% 3.81%
CloudMD Software & Services -91.12%-102.91%-8.74%

Vitalhub currently has a consensus target price of C$13.00, indicating a potential upside of 61.69%. Given Vitalhub's stronger consensus rating and higher probable upside, research analysts clearly believe Vitalhub is more favorable than CloudMD Software & Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
CloudMD Software & Services
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Vitalhub has a beta of 1.136195, suggesting that its share price is 14% more volatile than the broader market. Comparatively, CloudMD Software & Services has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

Summary

Vitalhub beats CloudMD Software & Services on 16 of the 17 factors compared between the two stocks.

How does Vitalhub compare to ZoomMed?

ZoomMed (CVE:ZMD) and Vitalhub (TSE:VHI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Vitalhub has higher revenue and earnings than ZoomMed. ZoomMed is trading at a lower price-to-earnings ratio than Vitalhub, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZoomMedC$10K203.39-C$1.49M-C$0.01N/A
VitalhubC$127.08M4.01C$3.35MC$0.1267.00

Vitalhub has a consensus target price of C$13.00, suggesting a potential upside of 61.69%. Given Vitalhub's stronger consensus rating and higher possible upside, analysts plainly believe Vitalhub is more favorable than ZoomMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZoomMed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Vitalhub
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

In the previous week, Vitalhub had 2 more articles in the media than ZoomMed. MarketBeat recorded 2 mentions for Vitalhub and 0 mentions for ZoomMed. Vitalhub's average media sentiment score of 0.47 beat ZoomMed's score of 0.00 indicating that Vitalhub is being referred to more favorably in the news media.

Company Overall Sentiment
ZoomMed Neutral
Vitalhub Neutral

25.6% of Vitalhub shares are held by institutional investors. 18.6% of Vitalhub shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vitalhub has a net margin of 5.89% compared to ZoomMed's net margin of 0.00%. Vitalhub's return on equity of 2.79% beat ZoomMed's return on equity.

Company Net Margins Return on Equity Return on Assets
ZoomMedN/A N/A N/A
Vitalhub 5.89%2.79%3.81%

Summary

Vitalhub beats ZoomMed on 15 of the 16 factors compared between the two stocks.

Get Vitalhub News Delivered to You Automatically

Sign up to receive the latest news and ratings for VHI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VHI vs. The Competition

Export
MetricVitalhubHealthcare Technology IndustryHealthcare SectorTSE Exchange
Market CapC$509.25MC$1.72BC$7.17BC$12.49B
Dividend YieldN/A4.71%2.53%6.25%
P/E Ratio67.0021.04272.9939.34
Price / Sales4.0183.08612.359.85
Price / CashN/A31.8777.8282.29
Price / Book1.867.3212.854.71
Net IncomeC$3.35M-C$26.60MC$3.47BC$299.09M
7 Day Performance-6.62%-0.57%1.25%-0.25%
1 Month Performance13.40%10.39%5.81%3.15%
1 Year Performance-31.40%-15.65%25.76%28.90%

Vitalhub Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VHI
Vitalhub
2.3541 of 5 stars		C$8.04
-2.3%		C$13.00
+61.7%		-30.7%C$509.25MC$127.08M67.002,250
CARE
Dialogue Health Technologies
N/AN/AN/AN/AC$345.36MC$95.88MN/A730
ADK
DIAGNOS
N/AC$0.41
+1.2%		N/A+84.6%C$48.77MC$65.48KN/AN/A
RHT
Reliq Health Technologies
N/AC$0.22
flat		N/A+0.0%C$46.65MN/AN/A12,600
DOC
CloudMD Software & Services
N/AC$0.04
flat		N/A+0.0%C$10.66MC$90.91MN/A200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:VHI) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Anthropic’s confidential SEC filing — and the public ticker that holds it
Anthropic filed confidentially for an IPO, and its annualized revenue run rate reportedly surged to $65 billio...
The Oxford Club | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Near retirement? Buy this stock
On August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...
Stansberry Research | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel